...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Question for the board!
Reply New Message
Prev Message Back To Forum Threaded View Next Message

acccchhh,,,,,the costing is not that prohibitive,,,,,,,,,,,,;

    TSX Venture Exchange
Listing Fees   $7,500 - $40,000
Accounting and Auditing Fees   $25,000 - $100,000
Legal Fees   $75,000+
Underwriters' Commission   Up to 12 %

------------------------------------------------------------------

                                          $ 150,000   Mid range costing.

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply